Literature DB >> 10378761

Respiratory depression in children receiving diazepam for acute seizures: a prospective study.

E Norris1, O Marzouk, A Nunn, J McIntyre, I Choonara.   

Abstract

The aim of this study was to determine the incidence of respiratory depression following the use of diazepam in children presenting with seizures. All children presenting with seizures to a children's A & E department over a period of 9 months were studied prospectively. Respiratory depression was defined as a fall in respiratory rate or oxygen saturation, or apnoea resulting in ventilation or resuscitation with bag-and-mask oxygen. There were 130 patient episodes involving 97 children who received treatment for their seizures before admission and/or in the A & E department. Administration of diazepam resulted in 122 patient episodes. The route of administration was rectal in 91 episodes, intravenous in 12 episodes, and both rectal and intravenous in 19 episodes. Eleven children had respiratory depression in relation to diazepam administration. Eight of these children required ventilation. The overall incidence of respiratory depression following the use of diazepam was 9%. The incidence of respiratory depression following diazepam given intravenously or rectally is high. The use of diazepam as first-line therapy for children with acute seizures needs to be reviewed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10378761     DOI: 10.1017/s0012162299000742

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  14 in total

1.  Intranasal midazolam for treating febrile seizures in children. Caution is advised in interpreting trial conclusions.

Authors:  T Johnson
Journal:  BMJ       Date:  2001-01-13

Review 2.  Drug trials in children: problems and the way forward.

Authors:  S Conroy; J McIntyre; I Choonara; T Stephenson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

3.  Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions.

Authors:  B R Ogutu; C R J C Newton; J Crawley; S N Muchohi; G O Otieno; G Edwards; K Marsh; G O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 4.  The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party.

Authors:  R Appleton; I Choonara; T Martland; B Phillips; R Scott; W Whitehouse
Journal:  Arch Dis Child       Date:  2000-11       Impact factor: 3.791

5.  Surveillance for fatal suspected adverse drug reactions in the UK.

Authors:  A Clarkson; I Choonara
Journal:  Arch Dis Child       Date:  2002-12       Impact factor: 3.791

6.  Inappropriate emergency management of status epilepticus in children contributes to need for intensive care.

Authors:  R F M Chin; L Verhulst; B G R Neville; M J Peters; R C Scott
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

7.  Predictors of anti-convulsant treatment failure in children presenting with malaria and prolonged seizures in Kampala, Uganda.

Authors:  Arthur Mpimbaza; Sarah G Staedke; Grace Ndeezi; Justus Byarugaba; Philip J Rosenthal
Journal:  Malar J       Date:  2009-06-29       Impact factor: 2.979

Review 8.  Safety of Diastat, a rectal gel formulation of diazepam for acute seizure treatment.

Authors:  John M Pellock
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions.

Authors:  Simon N Muchohi; Kenneth Obiero; Charles R J C Newton; Bernhards R Ogutu; Geoffrey Edwards; Gilbert O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2007-07-17       Impact factor: 4.335

10.  Response to diazepam in children with malaria-induced seizures.

Authors:  M L Ikumi; S N Muchohi; E O Ohuma; G O Kokwaro; C R J C Newton
Journal:  Epilepsy Res       Date:  2008-09-19       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.